tiprankstipranks
Advertisement
Advertisement

CRVO Stock Latest News

Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
RatingsNeflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
8d ago
CRVO
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
PremiumCompany Announcements
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
9d ago
8K
CRVO
CervoMed presents neflamapimod MRI data
PremiumThe Fly
CervoMed presents neflamapimod MRI data
9d ago
CRVO
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
PremiumCompany Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
24d ago
8K
CRVO
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
PremiumCompany Announcements
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
1M ago
8K
CRVO
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
PremiumCompany AnnouncementsCervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
1M ago
8K
CRVO
CervoMed’s neflamapimod shows efficacy in dementia with DLB
Premium
The Fly
CervoMed’s neflamapimod shows efficacy in dementia with DLB
1M ago
CRVO
CervoMed price target lowered to $11 from $19 at Roth Capital
Premium
The Fly
CervoMed price target lowered to $11 from $19 at Roth Capital
1M ago
CRVO
CervoMed price target raised to $21 from $15 at Chardan
PremiumThe Fly
CervoMed price target raised to $21 from $15 at Chardan
1M ago
CRVO
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
PremiumCompany Announcements
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
2M ago
8K
CRVO
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
PremiumRatings
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
2M ago
CRVO
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
PremiumThe Fly
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
2M ago
CRVO
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
PremiumRatingsCervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
2M ago
CRVO
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
Premium
Company Announcements
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
2M ago
CRVO
CervoMed announces presentations at AP/PD 2026 scientific conference
Premium
The Fly
CervoMed announces presentations at AP/PD 2026 scientific conference
2M ago
CRVO
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
PremiumMarket News
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
2M ago
CRVO
TCRX
CervoMed Advances Neflamapimod With Phase 1 Completion
PremiumCompany Announcements
CervoMed Advances Neflamapimod With Phase 1 Completion
2M ago
8K
CRVO
CervoMed completes Phase 1 volunteer study for neflamapimod
PremiumThe Fly
CervoMed completes Phase 1 volunteer study for neflamapimod
2M ago
CRVO
CervoMed’s Neflamapimod Added to U.K. ALS Platform
PremiumCompany Announcements
CervoMed’s Neflamapimod Added to U.K. ALS Platform
2M ago
8K
CRVO
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
PremiumRatingsCervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
2M ago
CRVO
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
Premium
The Fly
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
2M ago
CRVO
CervoMed Releases Updated Investor Presentation and Business Overview
Premium
Company Announcements
CervoMed Releases Updated Investor Presentation and Business Overview
4M ago
8K
CRVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >